Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PTLA

Portola Pharmaceuticals (PTLA) Stock Price, News & Analysis

Portola Pharmaceuticals logo

About Portola Pharmaceuticals Stock (NASDAQ:PTLA)

Advanced Chart

Key Stats

Today's Range
$18.03
$18.03
50-Day Range
$18.03
$18.03
52-Week Range
$5.31
$31.73
Volume
N/A
Average Volume
3.17 million shs
Market Capitalization
$1.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portola Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PTLA Stock News Headlines

Portola Middle
Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
Fault lines in Portola Valley
Portola-Butler Continuation High School
Eagle Pharmaceuticals
See More Headlines

PTLA Stock Analysis - Frequently Asked Questions

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.14. The company's revenue for the quarter was up 18.9% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Portola Pharmaceuticals investors own include Lexicon Pharmaceuticals (LXRX), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Amarin (AMRN), Editas Medicine (EDIT), Exelixis (EXEL) and Geron (GERN).

Company Calendar

Last Earnings
5/11/2020
Today
8/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PTLA
CIK
1269021
Fax
N/A
Employees
324
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($4.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$290.66 million
Net Margins
-232.73%
Pretax Margin
N/A
Return on Equity
-267.86%
Return on Assets
-54.66%

Debt

Debt-to-Equity Ratio
4.77
Current Ratio
4.87
Quick Ratio
4.82

Sales & Book Value

Annual Sales
$116.64 million
Price / Sales
12.13
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.67 per share
Price / Book
10.80

Miscellaneous

Outstanding Shares
78,484,000
Free Float
N/A
Market Cap
$1.42 billion
Optionable
Optionable
Beta
2.32
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:PTLA) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners